Adis Journals
Browse
Summary slide.png (137.11 kB)

Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 MG Versus Empagliflozin 25 MG for Treatment of Patients with Type 2 Diabetes in the UK Setting

Download (137.11 kB)
media
posted on 2021-01-06, 15:24 authored by Matthew Capehorn, Nino Hallén, James Baker-Knight, Divina Glah, Barnaby Hunt

Article full text


The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2021.

History

Usage metrics

    Diabetes Therapy

    Categories

    Keywords

    Cost-effectivenessCost-utilityDiabetes mellitusEmpagliflozinGLP-1 receptor agonistSemaglutideSGLT-2 inhibitorUnited Kingdom

    Licence

    CC BY-NC 4.0

    Exports